Biostate AI, a deeptech startup specializing in artificial intelligence and RNA sequencing, has secured $12 million in a Series A funding round led by venture capital firm Accel. Additional participants include Gaingels, Mana Ventures, InfoEdge Ventures, and existing investors Matter Venture Partners, Vision Plus Capital, and Catapult Ventures.
Advancing RNA Sequencing with AI
Founded by former professors and serial entrepreneurs David Zhang (ex-Rice University) and Ashwin Gopinath (ex-MIT), Biostate AI aims to build a "foundation model for molecular medicine." The company’s goal is to expand access to RNA sequencing (RNAseq)—a cornerstone of precision medicine—by reducing costs, improving data quality, and applying generative AI to extract actionable insights from the human transcriptome.
Biostate AI’s platform is already being utilized in over 150 pilot projects, including collaborations with Cornell University for leukemia research and the Accelerated Cure Project for multiple sclerosis. Since going commercial two quarters ago, the company has processed over 10,000 RNA samples.
Innovative Technologies for Precision Medicine
RNAseq has traditionally been a powerful but costly and technically fragmented method for tracking real-time gene expression and health markers. Biostate AI addresses these challenges through proprietary wet-lab techniques and AI-based analysis that can scale like modern software products.
Key proprietary technologies include:
-
BIRT (Biostate’s Integrated RNA Technology): An innovative multiplexing process that processes multiple tissue samples simultaneously, significantly reducing sequencing costs.
- PERD: A signal-filtering method that removes analytical noise in RNA datasets caused by variability between labs and equipment.
These innovations allow customers to run 2-3 times more samples within the same budget. With this data advantage, Biostate is building large language model (LLM)-style generative models trained on RNA sequences to predict disease evolution, recurrence, and treatment responses.
"Just as ChatGPT learned from the internet’s text, we’re training our models on the grammar of biology from billions of RNA expressions," said Ashwin Gopinath, co-founder and CTO.
From Diagnostics to Therapeutics
While Biostate’s initial focus is on RNAseq services for research labs and biotech companies in the U.S., its long-term ambition is to become an end-to-end platform for precision diagnostics and therapeutics. Its stack includes Quantaquill, a generative AI tool that drafts publication-ready manuscripts from clinical datasets—streamlining scientific writing alongside biological discovery.
The startup is also building a large, consented, de-identified dataset of RNA profiles, enabling the development of disease-specific predictive models. "We’re moving the entire diagnostics workflow closer to the patient," said David Zhang, co-founder and CEO.
Zhang, who previously invented several DNA diagnostic tools at Rice, described Biostate as a natural progression: "Every diagnostic I’ve built was about bringing answers faster. Biostate takes the biggest leap yet—by making full-transcriptome sequencing affordable."
Gopinath, whose work is personally motivated by his wife’s leukemia diagnosis, added: "We’re not just trying to predict disease. Eventually, we want to eliminate it."
Investor Confidence in Biostate’s AI-First Approach
"Biostate is doing for medicine what OpenAI did for text: scaling data collection so that AI can finally work," said Shekhar Kirani, Partner at Accel. "By combining generative AI with next-gen wetlab innovation, they’re laying the foundation for truly personalized, scalable healthcare."
To date, Biostate has raised over $20 million, including a prior seed round backed by deep-tech angels like Dario Amodei (Anthropic), Emily Leproust (Twist Bioscience), and Mike Schnall-Levin (10X Genomics).
With offices in Houston, Palo Alto, Bengaluru, and Shanghai, Biostate is positioning itself as a global player in molecular AI, with plans to expand collaborations in oncology, cardiovascular disease, and autoimmune disorders in the upcoming fiscal year.
The Future of Precision Medicine
Biostate AI’s innovative approach to RNA sequencing and AI-driven analysis represents a significant advancement in precision medicine. By reducing costs and improving data quality, the company is making RNAseq more accessible to researchers and clinicians, potentially leading to more personalized and effective treatments for a variety of diseases.
As the company continues to grow and expand its collaborations, it will be interesting to see how its technologies impact the broader field of molecular medicine. Will Biostate AI’s approach become the new standard in RNA sequencing and precision diagnostics?
For more information about Biostate AI and its technologies, visit their website.
